Characterization of B16 melanoma-specific cytotoxic T lymphocytes

Mamoru Harada, Koji Tamada, Koichiro Abe, Tieli Li, Yasuhiro Onoe, Hitoshi Tada, Katsunori Tatsugami, Takashi Ando, Genki Kimura, Kikuo Nomoto

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A B16 melanoma-specific CD8+ T cell line (AB1) was established from the spleen cells of C57BL/6 mice cured of B16 melanoma with interleukin (IL)-12 treatment. The ABl line exclusively used T cell receptor V(β11). The AB1 cells exhibited a cytolytic activity against both syngeneic B16 melanoma and allogeneic P815 mastocytoma, whereas a cold inhibition assay revealed specificity of the AB1 cells against B16 melanoma. Their lostability to kill a class I loss variant of B16 melanoma was restored by the transfection of H- 2K(b) gene. In addition, their interferon (IFN)-γ production was significantly suppressed by the addition of anti-H-2K(b) monoclonal antibody, and RT-PCR analysis showed that the AB1 line expressed the mRNA encoding IFN- γ, but not IL-4 or IL-10. The experiment using synthetic peptides of tyrosinase-related protein-2 (TRP-2) revealed that the AB1 cells could recognize TRP-2181-188 peptide. Moreover, the AB1 cells showed an in vivo antitumor effect against established pulmonary metastases of B16 melanoma. Overall, these results indicate that the Tcl-type V(β11) + AB1 cells exert an antitumor activity against syngeneic B16 melanoma through recognition of TRP-2181-188 peptide in an H-2K(b)-restricted manner.

Original languageEnglish
Pages (from-to)198-204
Number of pages7
JournalCancer Immunology Immunotherapy
Volume47
Issue number4
DOIs
Publication statusPublished - Dec 1 1998

Fingerprint

Experimental Melanomas
Cytotoxic T-Lymphocytes
Interferons
Peptides
Mastocytoma
Interleukin-12
T-Cell Antigen Receptor
Inbred C57BL Mouse
Interleukin-4
Interleukin-10
Transfection
Spleen
Monoclonal Antibodies
Neoplasm Metastasis
T-Lymphocytes
Cell Line
Polymerase Chain Reaction
Lung
Messenger RNA
Genes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Harada, M., Tamada, K., Abe, K., Li, T., Onoe, Y., Tada, H., ... Nomoto, K. (1998). Characterization of B16 melanoma-specific cytotoxic T lymphocytes. Cancer Immunology Immunotherapy, 47(4), 198-204. https://doi.org/10.1007/s002620050521

Characterization of B16 melanoma-specific cytotoxic T lymphocytes. / Harada, Mamoru; Tamada, Koji; Abe, Koichiro; Li, Tieli; Onoe, Yasuhiro; Tada, Hitoshi; Tatsugami, Katsunori; Ando, Takashi; Kimura, Genki; Nomoto, Kikuo.

In: Cancer Immunology Immunotherapy, Vol. 47, No. 4, 01.12.1998, p. 198-204.

Research output: Contribution to journalArticle

Harada, M, Tamada, K, Abe, K, Li, T, Onoe, Y, Tada, H, Tatsugami, K, Ando, T, Kimura, G & Nomoto, K 1998, 'Characterization of B16 melanoma-specific cytotoxic T lymphocytes', Cancer Immunology Immunotherapy, vol. 47, no. 4, pp. 198-204. https://doi.org/10.1007/s002620050521
Harada, Mamoru ; Tamada, Koji ; Abe, Koichiro ; Li, Tieli ; Onoe, Yasuhiro ; Tada, Hitoshi ; Tatsugami, Katsunori ; Ando, Takashi ; Kimura, Genki ; Nomoto, Kikuo. / Characterization of B16 melanoma-specific cytotoxic T lymphocytes. In: Cancer Immunology Immunotherapy. 1998 ; Vol. 47, No. 4. pp. 198-204.
@article{afd8bbdc03f347ed8559bb8a4d2fef9a,
title = "Characterization of B16 melanoma-specific cytotoxic T lymphocytes",
abstract = "A B16 melanoma-specific CD8+ T cell line (AB1) was established from the spleen cells of C57BL/6 mice cured of B16 melanoma with interleukin (IL)-12 treatment. The ABl line exclusively used T cell receptor V(β11). The AB1 cells exhibited a cytolytic activity against both syngeneic B16 melanoma and allogeneic P815 mastocytoma, whereas a cold inhibition assay revealed specificity of the AB1 cells against B16 melanoma. Their lostability to kill a class I loss variant of B16 melanoma was restored by the transfection of H- 2K(b) gene. In addition, their interferon (IFN)-γ production was significantly suppressed by the addition of anti-H-2K(b) monoclonal antibody, and RT-PCR analysis showed that the AB1 line expressed the mRNA encoding IFN- γ, but not IL-4 or IL-10. The experiment using synthetic peptides of tyrosinase-related protein-2 (TRP-2) revealed that the AB1 cells could recognize TRP-2181-188 peptide. Moreover, the AB1 cells showed an in vivo antitumor effect against established pulmonary metastases of B16 melanoma. Overall, these results indicate that the Tcl-type V(β11) + AB1 cells exert an antitumor activity against syngeneic B16 melanoma through recognition of TRP-2181-188 peptide in an H-2K(b)-restricted manner.",
author = "Mamoru Harada and Koji Tamada and Koichiro Abe and Tieli Li and Yasuhiro Onoe and Hitoshi Tada and Katsunori Tatsugami and Takashi Ando and Genki Kimura and Kikuo Nomoto",
year = "1998",
month = "12",
day = "1",
doi = "10.1007/s002620050521",
language = "English",
volume = "47",
pages = "198--204",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Characterization of B16 melanoma-specific cytotoxic T lymphocytes

AU - Harada, Mamoru

AU - Tamada, Koji

AU - Abe, Koichiro

AU - Li, Tieli

AU - Onoe, Yasuhiro

AU - Tada, Hitoshi

AU - Tatsugami, Katsunori

AU - Ando, Takashi

AU - Kimura, Genki

AU - Nomoto, Kikuo

PY - 1998/12/1

Y1 - 1998/12/1

N2 - A B16 melanoma-specific CD8+ T cell line (AB1) was established from the spleen cells of C57BL/6 mice cured of B16 melanoma with interleukin (IL)-12 treatment. The ABl line exclusively used T cell receptor V(β11). The AB1 cells exhibited a cytolytic activity against both syngeneic B16 melanoma and allogeneic P815 mastocytoma, whereas a cold inhibition assay revealed specificity of the AB1 cells against B16 melanoma. Their lostability to kill a class I loss variant of B16 melanoma was restored by the transfection of H- 2K(b) gene. In addition, their interferon (IFN)-γ production was significantly suppressed by the addition of anti-H-2K(b) monoclonal antibody, and RT-PCR analysis showed that the AB1 line expressed the mRNA encoding IFN- γ, but not IL-4 or IL-10. The experiment using synthetic peptides of tyrosinase-related protein-2 (TRP-2) revealed that the AB1 cells could recognize TRP-2181-188 peptide. Moreover, the AB1 cells showed an in vivo antitumor effect against established pulmonary metastases of B16 melanoma. Overall, these results indicate that the Tcl-type V(β11) + AB1 cells exert an antitumor activity against syngeneic B16 melanoma through recognition of TRP-2181-188 peptide in an H-2K(b)-restricted manner.

AB - A B16 melanoma-specific CD8+ T cell line (AB1) was established from the spleen cells of C57BL/6 mice cured of B16 melanoma with interleukin (IL)-12 treatment. The ABl line exclusively used T cell receptor V(β11). The AB1 cells exhibited a cytolytic activity against both syngeneic B16 melanoma and allogeneic P815 mastocytoma, whereas a cold inhibition assay revealed specificity of the AB1 cells against B16 melanoma. Their lostability to kill a class I loss variant of B16 melanoma was restored by the transfection of H- 2K(b) gene. In addition, their interferon (IFN)-γ production was significantly suppressed by the addition of anti-H-2K(b) monoclonal antibody, and RT-PCR analysis showed that the AB1 line expressed the mRNA encoding IFN- γ, but not IL-4 or IL-10. The experiment using synthetic peptides of tyrosinase-related protein-2 (TRP-2) revealed that the AB1 cells could recognize TRP-2181-188 peptide. Moreover, the AB1 cells showed an in vivo antitumor effect against established pulmonary metastases of B16 melanoma. Overall, these results indicate that the Tcl-type V(β11) + AB1 cells exert an antitumor activity against syngeneic B16 melanoma through recognition of TRP-2181-188 peptide in an H-2K(b)-restricted manner.

UR - http://www.scopus.com/inward/record.url?scp=0032431002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032431002&partnerID=8YFLogxK

U2 - 10.1007/s002620050521

DO - 10.1007/s002620050521

M3 - Article

VL - 47

SP - 198

EP - 204

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 4

ER -